Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Amicus gets hit with an 'unexpected' setback on a gene therapy tapped to lead $600M SPAC spinout

4 years ago

Bristol Myers takes a swing at 'off-the-shelf' cell therapies in $150M cash licensing pact with Century

4 years ago

Continuing push beyond Covid-19 vaccines, Moderna partners with 'CAR-M' biotech on in vivo cancer cell therapies

4 years ago

Allogene wins a major reprieve for its leading off-the-shelf cell therapy pipeline

4 years ago

Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic

4 years ago

How durable is durable? BioMarin gears up to bring hemophilia A gene therapy to FDA again with 2-year data

4 years ago

Pfizer, the new master of mRNA delivery, teams up with Beam to ship base editors straight to target tissues

4 years ago

Bayer jumps on board Mammoth's ultra-small CRISPR tech with sights set first on the liver

4 years ago

Merck KGaA beefs up its mRNA work with a $780M buyout of a booming player

4 years ago

You know AAV and LNP. What about PLV? Eli Lilly lines up new vehicle to deliver its genetic medicines

4 years ago

Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs

4 years ago

Can RNA editing take Atlas startup where Vertex couldn't go? Korro lands $116M to find out

4 years ago

Gene therapy 3.0 efforts net SalioGen a nine-figure Series B, but much remains under wraps

4 years ago

‘Disappointing’ ViaCyte data raise questions about future of company’s attempted diabetes cure

4 years ago

Novartis unwraps $1.5B gene therapy buyout — beefing up arsenal against retinal diseases

4 years ago

One of Pfizer’s Duchenne gene therapy trials put on hold in wake of patient death as high-dose AAV concerns still cloud field

4 years ago

Roche's Spark invests $575M for new gene therapy center in central Philadelphia as part of Drexel partnership

4 years ago

Pfizer opens doors at newest gene therapy site in NC as part of $800M push into next-gen drugs

4 years ago

IN8bio's 'off-the-shelf' gamma delta T cells stave off relapse for high-risk leukemia patients in very early data cut

4 years ago

Hopes for non-viral gene therapy take a blow as Generation Bio announces significant setback

4 years ago

#ASH21: The Jay Bradner interview: 'We're working up a goodly number of deals'

4 years ago

Could the next gene therapy manufacturing hub be Cincinnati? A $100M bet says yes

4 years ago

ASH: Sanofi uncorks late-stage data for RNAi drug fitusiran in hemophilia, with all eyes on safety profile

4 years ago

Bristol Myers antes up on a $920M partnership play for a next-gen — but early stage — bispecific with a couple of unique twists

4 years ago

First page Previous page 32 33 343536 37 38 Next page Last page